for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Calithera Biosciences Inc

CALA.OQ

Latest Trade

3.70USD

Change

-0.19(-4.77%)

Volume

104,916

Today's Range

3.62

 - 

3.91

52 Week Range

3.43

 - 

6.90

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.88
Open
3.91
Volume
104,916
3M AVG Volume
7.56
Today's High
3.91
Today's Low
3.62
52 Week High
6.90
52 Week Low
3.43
Shares Out (MIL)
53.77
Market Cap (MIL)
208.65
Forward P/E
-2.08
Dividend (Yield %)
--

Next Event

Calithera Biosciences Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Calithera Biosciences Says Q2 Loss Per Share $0.58

Calithera Biosciences Initiates Phase 1/2 Trial Of Telaglenastat

Calithera Biosciences, Inc. Prices Public Offering Of 12,500,000 Shares Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Calithera Biosciences Inc

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.

Industry

Biotechnology & Drugs

Contact Info

343 Oyster Point Blvd # 200

+1.650.8701000

http://www.calithera.com/

Executive Leadership

Susan M. Molineaux

President, Chief Executive Officer, Co-Founder, Director

Sumita Ray

Senior Vice President, Chief Compliance Officer, General Counsel

Christopher J. Molineaux

Senior Vice President - Development

Eric B. Sjogren

Senior Vice President - Drug Discovery

Stephanie Wong

Vice President - Finance, Secretary

Key Stats

1.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.950

2017

-0.840

2018

-1.490

2019(E)

-1.861
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.50
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-58.38
Return on Equity (TTM)
-52.98

Latest News

BRIEF-Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 In Combination With Cabozantinib For Treatment Of Patients With Advanced Renal Cell Carcinoma

* CALITHERA BIOSCIENCES ANNOUNCES FDA FAST TRACK DESIGNATION GRANTED TO CB-839 IN COMBINATION WITH CABOZANTINIB FOR TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage:

BRIEF-Calithera Biosciences Qtrly Net Loss From Operations $11.0 Mln

* CALITHERA BIOSCIENCES REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

BRIEF-Calithera Biosciences Says Plans To Initiate A Global, Randomized Phase 2 Trial Of CB-839 In Combination With Cabozantinib In Q2 Of 2018

* CALITHERA BIOSCIENCES INC - PLAN TO INITIATE A GLOBAL, RANDOMIZED PHASE 2 TRIAL OF CB-839 IN COMBINATION WITH CABOZANTINIB IN Q2 OF 2018 Source text for Eikon: Further company coverage:

BRIEF-Calithera Biosciences expands clinical collaboration with Bristol-Myers Squibb

* Initial results from Phase 2 study of CB-839 in combination with opdivo® (nivolumab) to be presented at the Society for Immunotherapy of Cancer Meeting

BRIEF-Calithera Biosciences Q3 operating loss per share $0.17

* Calithera biosciences reports third quarter 2017 financial results and recent highlights

BRIEF-Calithera Biosciences files for common stock offering of up to $250 mln

* Calithera Biosciences Inc files for common stock offering of up to $250 million - SEC filing Source text: (http://bit.ly/2hHfdIt) Further company coverage:

BRIEF-Calithera Biosciences reports Q2 operating loss per share $0.15

* Calithera Biosciences reports second quarter 2017 financial results and recent highlights

BRIEF-Calithera Biosciences initiates randomized phase 2 combination trial of CB-839 in patients with renal cell carcinoma

* Calithera Biosciences initiates a randomized phase 2 combination trial of CB-839 in patients with renal cell carcinoma

BRIEF-Calithera announces clinical data from product candidate CB-1158

* Calithera Biosciences Inc - clinical data from its product candidate CB-1158, a first-in-class arginase inhibitor

BRIEF-Bristol-Myers Squibb, Calithera Biosciences expand collaboration

* Bristol-Myers Squibb and Calithera Biosciences expand collaboration evaluating opdivo (nivolumab) in combination with CB-839 into non-small cell lung cancer and melanoma

BRIEF-Calithera Biosciences reports Q1 operating loss $0.22/shr

* Calithera Biosciences reports first quarter 2017 financial results and recent highlights

BRIEF-Calithera to receive $12 mln milestone payment from Incyte

* Calithera to receive $12 million milestone payment from Incyte for achievement of pharmacokinetic and pharmacodynamic goals in Phase 1 study Source text for Eikon: Further company coverage:

BRIEF-Calithera Biosciences prices public offering of 6,830,000 shares of common stock

* Calithera biosciences, inc. Prices public offering of 6,830,000 shares of common stock Source text for Eikon: Further company coverage:

BRIEF-Calithera announces commencement of underwritten public offering of common stock

* Calithera biosciences, inc. Announces commencement of underwritten public offering of common stock

BRIEF-Calithera Biosciences qtrly loss per share $0.45

* Calithera biosciences reports fourth quarter and full year 2016 financial results and recent highlights

BRIEF-Hawkes Bay Master Investors (Cayman) L.P. reports 5.28 pct passive stake in Calithera Biosciences Inc

* Hawkes Bay Master Investors (Cayman) L.P. reports 5.28 percent passive stake in Calithera Biosciences Inc as on February 22, 2017 - SEC filing Source text for Eikon: [http://bit.ly/2lwx5ah] Further company coverage:

BRIEF-Viking Global Investors reports 7.8 pct passive stake in Calithera Biosciences

* Viking Global Investors Lp reports a 7.8 percent passive stake in Calithera Biosciences Inc as of Feb 8, 2017 - sec filing Source text: (http://bit.ly/2kJ7HOa) Further company coverage:

BRIEF-Incyte and Calithera Biosciences announce global collaboration to develop and commercialize CB-1158

* Incyte and calithera biosciences announce global collaboration to develop and commercialize CB-1158, a first-in-class, small molecule arginase inhibitor

BRIEF-Calithera Biosciences posts Q3 loss per share $0.44

* Calithera Biosciences reports third quarter 2016 financial results and recent highlights, and raises year-end cash guidance

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up